Nrg-Hn001- Randomized Phase II And Phase III Studies Of Individualized Treatment For Nasopharyngeal Carcinoma Based On Biomarker Epstein Barr Virus (Ebv) Deoxyribonucleic Acid (Dna)
Posted Date: May 15, 2019
- Investigator: Jordan Kharofa
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The goal of this study is to determine whether substituting adjuvant CDDP and 5-FU with gemcitabine and paclitaxel will result in superior progression-free survival.
Criteria:
To Be Eligible: Patients Must Have Stage Ii-Ivb Nasopharyngeal Cancer, Age 18 Or Older, Nonpregnant, No Prior Invasive Malignancy In Past 3 Years.
Keywords:
Head And Neck Cancer, Nasopharyngeal Carcinoma, Cancer, Head & Neck
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com